Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer

Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer

Abstract Background Although endocrine therapies, alone or in combination with CDK4/6 inhibitors, have led to notable improvements in the treatment of estrogen receptor-positive (ER+) breast cancer, progression is inevitable for most patients. We report dose escalation and expansion data from a tria...

Full description

Saved in:
Bibliographic Details
Main Authors: Erika Hamilton, Timothy Pluard, Judy S. Wang, Aki Morikawa, Stephen Johnston, E. Claire Dees, Christos Vaklavas, Anne Armstrong, Pamela Munster, Nisha Unni, Gail S. Wright, Fadi Kayali, Tingting Song, Yuanxin Rong, Kohei Yamaguchi, Dejan Juric
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Breast Cancer Research
Subjects:
H3B-6545
Breast cancer
Endocrine therapy
HER2-negative
Estrogen receptor-positive
Online Access:https://doi.org/10.1186/s13058-025-02069-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02069-8

Similar Items